1. Home
  2. ADPT vs BCC Comparison

ADPT vs BCC Comparison

Compare ADPT & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$21.28

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Boise Cascade L.L.C.

BCC

Boise Cascade L.L.C.

HOLD

Current Price

$75.61

Market Cap

2.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
BCC
Founded
2009
2004
Country
United States
United States
Employees
N/A
7680
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
RETAIL: Building Materials
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
ADPT
BCC
Price
$21.28
$75.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$17.78
$99.20
AVG Volume (30 Days)
4.0M
396.7K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
1.11%
EPS Growth
63.89
N/A
EPS
N/A
0.50
Revenue
$276,976,000.00
$4,995,290,000.00
Revenue This Year
$3.98
$3.41
Revenue Next Year
$22.72
$4.76
P/E Ratio
N/A
$151.86
Revenue Growth
54.77
12.71
52 Week Low
$9.96
$65.00
52 Week High
$22.80
$95.00

Technical Indicators

Market Signals
Indicator
ADPT
BCC
Relative Strength Index (RSI) 66.83 55.21
Support Level $15.08 $71.49
Resistance Level N/A $78.96
Average True Range (ATR) 1.27 2.88
MACD 0.33 0.47
Stochastic Oscillator 76.67 49.84

Price Performance

Historical Comparison
ADPT
BCC

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: